Literature DB >> 27462004

Patient selection and perioperative outcomes are similar between targeted and nontargeted hospitals (in the National Surgical Quality Improvement Program) for abdominal aortic aneurysm repair.

Peter A Soden1, Sara L Zettervall2, Klaas H J Ultee3, Jeremy D Darling1, John C McCallum1, Allen D Hamdan1, Mark C Wyers1, Marc L Schermerhorn4.   

Abstract

OBJECTIVE: The targeted vascular module in the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) consists of self-selected hospitals that choose to collect extra clinical details for better risk adjustment and improved procedure-specific outcomes. The purpose of this study was to compare patient selection and outcomes between targeted and nontargeted hospitals in the NSQIP regarding the operative management of abdominal aortic aneurysm (AAA).
METHODS: We identified all patients who underwent endovascular aneurysm repair (EVAR) or open AAA repair from 2011 to 2013 and compared cases by whether the operation took place in a targeted or nontargeted hospital. EVAR and open repair as well as intact and ruptured aneurysms were evaluated separately. Only variables contained in both modules were used to evaluate rupture status and operation type. All thoracoabdominal aneurysms were excluded. Univariate analysis was performed for intact and ruptured EVAR and open repair grouped by complexity, defined as visceral involvement in open repair and a compilation of concomitant procedures for EVAR. Multivariable models were developed to identify effect of hospital type on mortality.
RESULTS: There were 17,651 AAA repairs identified. After exclusion of aneurysms involving the thoracic aorta (n = 352), there were 1600 open AAA repairs at targeted hospitals (21% ruptured) and 2725 at nontargeted hospitals (19% ruptured) and 4986 EVARs performed at targeted hospitals (6.7% ruptured) and 7988 at nontargeted hospitals (5.2% ruptured). There was no significant difference in 30-day mortality rates between targeted and nontargeted hospitals for intact aneurysms (EVAR noncomplex, 1.8% vs 1.4% [P = .07]; open repair noncomplex, 4.2% vs 4.5% [P = .7]; EVAR complex, 5.0% vs 3.2% [P = .3]; open repair complex, 8.0% vs 6.0% [P = .2]). For ruptured aneurysms, again there was no difference in mortality between the targeted and nontargeted hospitals (EVAR noncomplex, 23% vs 25% [P = .4]; open repair noncomplex, 38% vs 34% [P = .2]; EVAR complex, 29% vs 33% [P = 1.0]; open repair complex, 27% vs 41% [P = .09]). Multivariable analysis further demonstrated that having an operation at a targeted vs nontargeted hospital had no impact on mortality for both intact and ruptured aneurysms (odds ratio, 1.1 [0.9-1.4] and 1.0 [0.8-1.3], respectively).
CONCLUSIONS: This analysis highlights the similarities between targeted and nontargeted hospitals within the NSQIP for AAA operative management and suggests that data from the targeted NSQIP, in terms of AAA management, are generalizable to all NSQIP hospitals.
Copyright © 2016 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27462004      PMCID: PMC5253340          DOI: 10.1016/j.jvs.2016.04.066

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  36 in total

1.  The effect of trainee involvement on perioperative outcomes of abdominal aortic aneurysm repair.

Authors:  Sebastian DiDato; Alik Farber; Denis Rybin; Jeffrey A Kalish; Mohammad H Eslami; Carla C Moreira; Nishant K Shah; Jeffrey J Siracuse
Journal:  J Vasc Surg       Date:  2015-09-10       Impact factor: 4.268

2.  Morbidity and mortality after use of iliac conduits for endovascular aortic aneurysm repair.

Authors:  Prateek K Gupta; Abhishek Sundaram; K Craig Kent
Journal:  J Vasc Surg       Date:  2015-04-30       Impact factor: 4.268

3.  Improved Surgical Outcomes for ACS NSQIP Hospitals Over Time: Evaluation of Hospital Cohorts With up to 8 Years of Participation.

Authors:  Mark E Cohen; Yaoming Liu; Clifford Y Ko; Bruce L Hall
Journal:  Ann Surg       Date:  2016-02       Impact factor: 12.969

4.  Relative importance of aneurysm diameter and body size for predicting abdominal aortic aneurysm rupture in men and women.

Authors:  Ruby C Lo; Bing Lu; Margriet T M Fokkema; Mark Conrad; Virendra I Patel; Mark Fillinger; Robina Matyal; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2013-12-30       Impact factor: 4.268

5.  Hospital and patient characteristics associated with death after surgery. A study of adverse occurrence and failure to rescue.

Authors:  J H Silber; S V Williams; H Krakauer; J S Schwartz
Journal:  Med Care       Date:  1992-07       Impact factor: 2.983

6.  Comparable mortality with open repair of complex and infrarenal aortic aneurysm.

Authors:  Virendra I Patel; Robert T Lancaster; Mark F Conrad; Glenn M Lamuraglia; Christopher J Kwolek; David C Brewster; Richard P Cambria
Journal:  J Vasc Surg       Date:  2011-07-01       Impact factor: 4.268

7.  Endovascular vs. open repair of abdominal aortic aneurysms in the Medicare population.

Authors:  Marc L Schermerhorn; A James O'Malley; Ami Jhaveri; Philip Cotterill; Frank Pomposelli; Bruce E Landon
Journal:  N Engl J Med       Date:  2008-01-31       Impact factor: 91.245

8.  Perioperative mortality of elective abdominal aortic aneurysm surgery. A clinical prediction rule based on literature and individual patient data.

Authors:  E W Steyerberg; J Kievit; J C de Mol Van Otterloo; J H van Bockel; M J Eijkemans; J D Habbema
Journal:  Arch Intern Med       Date:  1995-10-09

9.  Mortality from ruptured abdominal aortic aneurysms: clinical lessons from a comparison of outcomes in England and the USA.

Authors:  Alan Karthikesalingam; Peter J Holt; Alberto Vidal-Diez; Baris A Ozdemir; Jan D Poloniecki; Robert J Hinchliffe; Matthew M Thompson
Journal:  Lancet       Date:  2014-03-15       Impact factor: 79.321

10.  Purposeful selection of variables in logistic regression.

Authors:  Zoran Bursac; C Heath Gauss; David Keith Williams; David W Hosmer
Journal:  Source Code Biol Med       Date:  2008-12-16
View more
  6 in total

1.  Early reintervention after open and endovascular abdominal aortic aneurysm repair is associated with high mortality.

Authors:  Sarah E Deery; Thomas F X O'Donnell; Thomas C F Bodewes; Barbara A Dalebout; Alexander B Pothof; Katie E Shean; Jeremy D Darling; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2017-09-21       Impact factor: 4.268

2.  Treatment outcomes in diabetic patients with chronic limb-threatening ischemia.

Authors:  Patric Liang; Peter A Soden; Sara L Zettervall; Katie E Shean; Sarah E Deery; Raul J Guzman; Allen D Hamdan; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2018-03-22       Impact factor: 4.268

3.  In-hospital outcomes alone underestimate rates of 30-day major adverse events after carotid artery stenting.

Authors:  Patric Liang; Yoel Solomon; Nicholas J Swerdlow; Chun Li; Rens R B Varkevisser; Livia E V M de Guerre; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2020-02-13       Impact factor: 4.268

4.  In-hospital versus postdischarge major adverse events within 30 days following lower extremity revascularization.

Authors:  Patric Liang; Chun Li; Thomas F X O'Donnell; Ruby C Lo; Peter A Soden; Nicholas J Swerdlow; Marc L Schermerhorn
Journal:  J Vasc Surg       Date:  2018-10-06       Impact factor: 4.268

5.  Contemporary mortality after emergent open repair of complex abdominal aortic aneurysms.

Authors:  Christopher A Latz; Laura Boitano; Samuel Schwartz; Nicholas Swerdlow; Kirsten Dansey; Rens R B Varkevisser; Virendra Patel; Marc Schermerhorn
Journal:  J Vasc Surg       Date:  2020-04-29       Impact factor: 4.268

6.  Editor's Choice - Mortality is High Following Elective Open Repair of Complex Abdominal Aortic Aneurysms.

Authors:  Christopher A Latz; Laura Boitano; Samuel Schwartz; Nicholas Swerdlow; Kirsten Dansey; Rens R B Varkevisser; Virendra Patel; Marc L Schermerhorn
Journal:  Eur J Vasc Endovasc Surg       Date:  2020-10-09       Impact factor: 7.069

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.